Evidence · Journal club · continued

Journal club: STEP 4 and what a withdrawal design can prove — one year on posts 61–63

Evidence › Journal club number needed to treat estimand randomised trial effect size Closed

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

baseline_peakTL2Member24 Apr 2025#61

On post #57 — agreed on the reasoning, with one qualification.

TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.

0 likes 15mo

b.jansenTL2 Moderator27 Apr 2025#62

post #61 answers the question as asked. The question underneath it is different.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

26 likes 15mo

m.stephanopoulosTL3Regular29 Apr 2025#63

Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?

13 likes 15mo

This topic was referenced in

Journal club: FLOW and the renal composite, component by componentEvidence › Journal club · 91 replies
Journal club: how we handle discontinuation in obesity trialsEvidence › Journal club · 2 replies

This topic was closed 180 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Moved from Meta-analyses by j.mwangi. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
[2026 update] Journal club: FLOW and the renal composite, component by component Evidence › Journal club journal club randomised trial estimand Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…		2	21k	9d
Second pass at: Journal club: LEADER as the historical anchor Evidence › Journal club randomised trial journal club effect size estimand Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…	+75	81	2k	2y
[2026 update] Journal club: is percentage weight change the right endpoint? Evidence › Journal club effect size risk of bias randomised trial Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…	+105	118	18k	11mo
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Evidence › Journal club randomised trial effect size journal club risk of bias Solved Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with SCALE ( N Engl J…	+47	51	617	16mo
Journal club: SUSTAIN 6 and its retinopathy signal Evidence › Journal club estimand effect size risk of bias journal club Under review On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…	+110	122	46k	1d

Related topics — sharing the tags number needed to treat, estimand, randomised trial

Topic	Participants	Replies	Views	Activity
A well-designed study with a badly written abstract — does this still hold? Evidence › Study critique disputed confounding risk of bias Solved Closed A well-designed study with a badly written abstract — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med , 2021)…		2	28k	20mo
A 40-week log with the measurement method stated — does this still hold? Outcomes › Progress reports effect size DXA data table Solved A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Longitudinal report with the method stated,…	+1	5	14k	2mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+101	111	1.5k	18mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…	+149	159	30k	15mo